TrialCompass TCL
Back to results
Phase 3RecruitingPriority 1 · Highest priorityNCT05931263

A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL

ClinicalTrials.gov

Plain-language summary

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 65 Years years
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

C-BEAM Regimen (DRUG): Chidemide，carmustine, etoposide, cytarabine, and melphalan | BEAM Regimen (DRUG): carmustine, etoposide, cytarabine, and melphalan

Drugs / treatments
C-BEAM Regimen, BEAM Regimen
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL

NCT05931263

Phase: Phase 3 | Status: Recruiting | Priority: Highest

Plain-language summary

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 65 Years years
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

What's being tested

C-BEAM Regimen (DRUG): Chidemide，carmustine, etoposide, cytarabine, and melphalan | BEAM Regimen (DRUG): carmustine, etoposide, cytarabine, and melphalan

Drugs / treatments: C-BEAM Regimen, BEAM Regimen

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Randomized, open-label

Enrollment target: 104 patients

Primary endpoint: 2-y PFS

Ages: 18 Years to 65 Years

Start date: 2023-06-01 | Est. completion: 2028-02

Locations

0 US sites · 1 total

Contact

wei xu | xuwei10000@hotmail.com | 86-25-68302182

Sponsor: The First Affiliated Hospital with Nanjing Medical University (OTHER)

Tags

All T-cell lymphomas · Newly diagnosed

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05931263

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.